GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cerus Corp (NAS:CERS) » Definitions » Shiller PE Ratio

Cerus (CERS) Shiller PE Ratio : (As of Apr. 27, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Cerus Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cerus Shiller PE Ratio Historical Data

The historical data trend for Cerus's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cerus Shiller PE Ratio Chart

Cerus Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cerus Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cerus's Shiller PE Ratio

For the Medical Devices subindustry, Cerus's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cerus's Shiller PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cerus's Shiller PE Ratio falls into.



Cerus Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cerus's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Cerus's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.01/129.4194*129.4194
=-0.010

Current CPI (Dec. 2023) = 129.4194.

Cerus Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.120 99.695 -0.156
201406 -0.160 100.560 -0.206
201409 -0.160 100.428 -0.206
201412 -0.250 99.070 -0.327
201503 -0.170 99.621 -0.221
201506 -0.170 100.684 -0.219
201509 -0.170 100.392 -0.219
201512 -0.150 99.792 -0.195
201603 -0.170 100.470 -0.219
201606 -0.180 101.688 -0.229
201609 -0.140 101.861 -0.178
201612 -0.130 101.863 -0.165
201703 -0.180 102.862 -0.226
201706 -0.160 103.349 -0.200
201709 -0.120 104.136 -0.149
201712 -0.100 104.011 -0.124
201803 -0.110 105.290 -0.135
201806 -0.100 106.317 -0.122
201809 -0.110 106.507 -0.134
201812 -0.120 105.998 -0.147
201903 -0.140 107.251 -0.169
201906 -0.130 108.070 -0.156
201909 -0.130 108.329 -0.155
201912 -0.120 108.420 -0.143
202003 -0.100 108.902 -0.119
202006 -0.090 108.767 -0.107
202009 -0.080 109.815 -0.094
202012 -0.090 109.897 -0.106
202103 -0.100 111.754 -0.116
202106 -0.090 114.631 -0.102
202109 -0.070 115.734 -0.078
202112 -0.050 117.630 -0.055
202203 -0.070 121.301 -0.075
202206 -0.050 125.017 -0.052
202209 -0.050 125.227 -0.052
202212 -0.080 125.222 -0.083
202303 -0.090 127.348 -0.091
202306 -0.070 128.729 -0.070
202309 -0.040 129.860 -0.040
202312 -0.010 129.419 -0.010

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cerus  (NAS:CERS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cerus Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cerus's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cerus (CERS) Business Description

Traded in Other Exchanges
Address
1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Executives
Eric Bjerkholt director 132 PURDURE AVENUE, KENGSINGTON CA 94708
Ann Lucena director C/O CERUS CORPORATION, 1220 CONCORD AVE. SUITE 600, CONCORD CA 94520
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
Gail Schulze director 3451 WELLS ROAD, MALVERN PA 19355
Laurence M Corash director C/O CERUS CORP, 2411 STENWELL DRIVE, CONCORD CA 94520
William Mariner Greenman officer: President, Cerus Europe C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Chrystal Menard officer: Chief Legal Officer C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Kevin Dennis Green officer: Chief Accounting Officer C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Richard J Benjamin officer: Chief Medical Officer 15 WHITE PINE ROAD, NEWTON MA 02464
Vivek K Jayaraman officer: Chief Commercial Officer 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Hua Shan director C/O CERUS CORPORATION, 1220 CONCORD AVE., STE. 600, CONCORD CA 94520
Carol Moore officer: SR. V.P. Regulatory, Clinical C/O CERUS CORPORATION, 2550 STANWELL DRIVE, CONCORD CA 94520
Timothy B Anderson director C/O JAN STERN REED BAXTER INTERNATIONAL, ONE BAXTER PARKWAY DF2 2W, DEERFIELD IL 60015
Timothy L. Moore director C/O KITE PHARMA, INC., 2225 COLORADO AVE., SANTA MONICA CA 90404
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451